

## **AbScreen**

AbGenomics licensing offer,  
Worldwide, except Asia.

---

In an interview at BIO 2002, Rong-Hwa Lin, CEO of AbGenomics, informed R&D focus that the company is seeking partners for the co-development of targets and potential therapeutics that arise from their proprietary platform technology, AbScreen. The technology can be used for the identification of binding reagents specific to post-translationally modified and native proteins through the screening of monoclonal antibody, phage display and combinatorial nucleic acid libraries. AbGenomics has identified several therapeutic and diagnostic targets for use in the development of therapeutics for rheumatoid arthritis, immune related diabetes, graft rejection and cancer. A molecule with potential in the treatment of systemic lupus has also been identified.

For future information on the licensing opportunities available, see next story.

## **AbGn 168**

AbGenomics licensing offer,  
Worldwide, except Asia.

---

AbGenomics' monoclonal antibody, AbGn 168, is available for licensing outside of Asia. The agent is undergoing preclinical evaluation in Taiwan and has complete proof of concept studies as a potential treatment for autoimmune disease and transplant rejection. The CEO of AbGenomics, Rong-Hwa Lin, informed R&D focus at BIO 2002, that phase I trials are expected to commence by end 2003. Preliminary animal model data indicates that the agent is effective without side effects.

AbGn 168 was generated using AbGenomics' proprietary AbScreen and AbProt technology. The AbProt technology platform generates monoclonal antibodies that

recognize antigens of native conformation, including post-translational modifications.

For further information on the licensing opportunities available, contact:

Rong-Hwa Lin  
CEO, AbGenomics  
2F No 32 Lane 358 Juikuang Road  
Neihu Taipei 114  
Taiwan

Tel: +886 2 2627 2707

Fax: +886 2 2627 2708

Email: [APRIL@abgenomics.com](mailto:APRIL@abgenomics.com)